This week at a symposium of cannabis experts hosted by the Royal Pharmaceutical Society of Great Britain (RPSGB) where the scientists from Israel and Spain said that a compound present in cannabis significantly slows memory problems caused by Alzheimer’s disease.
Ten years ago the RPSGB launched its protocols to demonstrate the therapeutic effectiveness of cannabis which led to Government-funded trials in Britain to explore the benefits for patients with multiple sclerosis and in the treatment of severe pain.
Professor Tony Moffat, chairman of the Symposium says progress has been made in the last ten years but more research is needed as there is considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain.
Alzheimer’s disease is the commonest form of dementia, which affects an estimated 24.3 million people worldwide. Most of us reading this blog is well aware that most cases of Alzheimers are actually Lyme Disease..